What is the current size and annual growth rate of the multivalent vaccines market?
The multivalent vaccines market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising public awareness for vaccination, increasing government support, increasing demand for pediatric multivalent vaccines, increasing funding for vaccine research, and rising demand for multivalent vaccines.
The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $13.32 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rising incidence of infectious illnesses, increasing numbers of geriatric population, increasing government and private sector investment, growing focus on vaccine safety and effectiveness, and growing focus on therapeutic vaccines. Major trends in the forecast period include greater emphasis on combination vaccines, integration of digital health technologies, development in mRNA technology, development of personalized vaccines, and increase in research activities.
Get Your Free Sample of The Global Multivalent Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19120&type=smp
Which major factors have contributed to the expansion of the multivalent vaccines market?
The rising incidences of infectious diseases are expected to propel the growth of the multivalent vaccines market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that spread through direct contact or contaminated surfaces, air, or water and can range from mild to severe. Global travel accelerates the spread of infectious diseases by allowing pathogens to quickly cross borders and infect new populations. Multivalent vaccines provide wider protection in infectious diseases by targeting multiple pathogen strains in one dose, cutting down the need for separate shots. This broad coverage boosts herd immunity and lowers disease prevalence, enhancing public health. For instance, in April 2024, according to the report published by TravelHealthPro, a UK-based website supported by the UK Health Security Agency, the UK reported 2,004 malaria cases in 2023, marking an increase from the 1,369 imported cases reported in 2022. Therefore, the rising incidences of infectious diseases are driving the growth of the multivalent vaccines market.
How is the multivalent vaccines market segmented?
The multivalent vaccinesmarket covered in this report is segmented –
1) By Type: Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines
2) By Disease: Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus
3) By Route Of Administration: Oral, Injectable
4) By Age Group: Pediatrics, Adults, Geriatrics
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines, Protein Conjugate Vaccines
2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines, Subunit Protein Vaccines, Virus-Like Particle Vaccines
3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines, Live Attenuated Viral Vaccines
4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines
5) By Recombinant Vaccines: Recombinant Protein Vaccines, Recombinant DNA Vaccines
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/multivalent-vaccines-global-market-report
Who are the top competitors in the multivalent vaccines market?
Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma corp., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., WestVac Biopharma Co. Ltd., VBI Vaccines Inc.
Which key trends are expected to influence the multivalent vaccines market in the coming years?
Major companies operating in the multivalent vaccines market are focused on developing advanced pentavalent vaccines to improve overall public health outcomes by offering broader protection in a single dose. A pentavalent vaccine is a multivalent vaccine designed to protect against five distinct pathogens or strains. Combining these protections into a single vaccine simplifies immunization schedules and enhances overall vaccine coverage. For instance, in December 2023, Panacea Biotec Ltd., an India-based biotechnology company, launched EasyFourPol. This vaccine is the world’s first fully liquid vaccine, protecting against five serious diseases such as diphtheria, tetanus, pertussis, polio, and invasive infections from Haemophilus influenzae Type B. This ready-to-use combination vaccine eliminates the need for preparation by healthcare workers, streamlining the vaccination process. It offers the same level of protection as single-antigen vaccines, reduces the number of clinic visits for children, and lowers overall immunization costs. Additionally, it enhances vaccination efficiency and minimizes environmental impact by reducing the need for vials, syringes, and packaging.
Which regional trends are influencing the multivalent vaccines market, and which area dominates the industry?
North America was the largest region in the multivalent vaccines market in 2024. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Multivalent Vaccines Market Report 2025 Offer?
The multivalent vaccines market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Multivalent vaccines are vaccines designed to protect against multiple strains or types of a single pathogen, or against several different pathogens, in a single dose. By including antigens from various strains or diseases, these vaccines generate immunity against several targets simultaneously, offering broader protection compared to monovalent vaccines, which focus on a single strain or pathogen.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19120
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
